Operations

CytRx Corporation Regains Nasdaq Listing Compliance

November 20, 2017

LOS ANGELES, Nov. 17, 2017 /PRNewswire/ — CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that it received written notification on November 16, 2017, from the NASDAQ Listing Qualifications Department that it has regained compliance with the minimum bid price requirement set forth in NASDAQ Listing Rule Section […]

NanoViricides Files Quarterly Report for Period Ending September 30, 2017

November 20, 2017

SHELTON, Conn., Nov. 20, 2017 /PRNewswire/ — NanoViricides, Inc. (NYSE MKT: NNVC) (the “Company”) a global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform (the “Company”), filed its quarterly report for its first quarter of financial year 2018 in a timely manner with the Securities and Exchange Commission […]

Sage Therapeutics Announces Closing of $345 Million Public Offering of Common Stock, Including Full Exercise of Option to Purchase Additional Shares

November 20, 2017

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Sage Therapeutics (Nasdaq: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced the closing of its previously announced underwritten public offering of common stock, including the exercise in full by the underwriters of their option to purchase an additional 529,411 shares at the public […]

AVEO Announces Appointment of Nikhil Mehta, Ph.D., as Senior Vice President of Regulatory and Quality Assurance

November 20, 2017

CAMBRIDGE, Mass.–(BUSINESS WIRE)–AVEO Oncology (NASDAQ: AVEO) today announced the appointment of Nikhil Mehta, Ph.D., as Senior Vice President of Regulatory and Quality Assurance, effective November 20, 2017. In this role, Dr. Mehta will oversee all aspects of regulatory, quality and technical operations for the company’s portfolio. Dr. Mehta brings to AVEO more than 25 years […]

Circle Pharma Announces Appointment of David Spellmeyer, PhD, as Chief Scientific Officer

November 20, 2017

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Circle Pharma, Inc., a developer of macrocycle therapeutics, today announced that David Spellmeyer, PhD, has been appointed as its chief scientific officer.   “His deep experience in rational drug design and discovery is an excellent fit for Circle as we extend our platform for macrocycle discovery and advance our therapeutic pipeline […]

Prima BioMed Changes Its Name to Immutep Ltd

November 20, 2017

SYDNEY, Australia, Nov. 20, 2017 (GLOBE NEWSWIRE) — Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) (“Prima” or the “Company”) has announced a rebranding of the Company from Prima BioMed Ltd to Immutep Ltd (“Immutep”) following shareholder approval at its Annual General Meeting on 17 November 2017. Following the acquisition of Immutep S.A.S (the Company’s 100% […]

Gamida Cell Appoints Julian Adams, Ph.D., Chairman and Chief Executive Officer

November 20, 2017

JERUSELUM, Israel and CAMBRIDGE, Mass., November 20, 2017 – Gamida Cell, a leading cellular and immune therapeutics company, today announced the appointment of Julian Adams, Ph.D., as chairman and chief executive officer. Dr. Adams brings more than 30 years of drug discovery and development experience to his new role as CEO of Gamida Cell. He […]

Pertinax Pharma appoints Nigel Brooksby as Chairman Former chairman of Sanofi to help drive the commercialization of Pertinax®

November 20, 2017

14 November 2017: Pertinax Pharma announces that Nigel Brooksby has been appointed as chairman of the company. His chief responsibilities will be to assist in corporate, strategic and business development moves into its commercialisation phase following the launch last month of Pertinax®. This unique technology which enables controlled and sustained release of the antimicrobial, chlorhexidine […]

OptimizeRx Launches Real-time Financial Messaging Directly Within Another Top 20 EHR, Amazing Charts, Providing Prescription Cost Savings at Point-of-Care

November 20, 2017

ROCHESTER, Mich. and WEST WARWICK, R.I., Nov. 20, 2017 (GLOBE NEWSWIRE) — OptimizeRx Corp. (OTCQB:OPRX), the nation’s leading provider of digital health messaging via electronic health records (EHRs), has directly integrated its financing messaging with Amazing Charts, a leading EHR and subsidiary of Harris Healthcare, to help patients save money and be better educated about […]

Quanticate launches statistical monitoring services following the ICH GCP E6(R2) addendum

November 20, 2017

LONDON (UK) – Quanticate, a data-focused clinical research organisation (CRO), has launched its centralised statistical monitoring service (https://www.quanticate.com/centralized-statistical-monitoring) as an extension of its statistical consultancy offering in response to recent amendments to the International Conference of Harmonisation (ICH) Good Clinical Practice (GCP) E6(R2) guidelines. The new service will offer Quanticate’s customers statistical consultancy that incorporates […]

Brainsway Reports Record Quarterly Revenues in Third Quarter of 2017

November 20, 2017

HACKENSACK, N.J., Nov. 20, 2017 (GLOBE NEWSWIRE) — Brainsway Ltd. (TASE:BRIN), a leader in the advanced non-invasive treatment of brain disorders, today announced the Company’s financial results for the third quarter ended September 30, 2017. The Company’s revenues for the third quarter of 2017 increased by 27% over the revenues in the second quarter of […]

WIRB-Copernicus Group Partners with Veeva Systems Inc.

November 20, 2017

WCG will create a seamless connection between WCG’s MyConnexus™ IRB document management web portal and Veeva Vault eTMF WIRB-Copernicus Group® (WCG™), the world’s leading provider of solutions that measurably improve the quality and efficiency of clinical research, today announced that it is partnering with Veeva Systems Inc. to improve the speed and accuracy of institutional review […]

AmpliPhi Biosciences Reports Third Quarter 2017 Financial Results and Business Highlights Six patients with life-threatening S. aureus or P. aeruginosa infections treated to date with AB-SA01 or AB-PA01 under expanded access in the U.S. and Australia

November 15, 2017

SAN DIEGO–(BUSINESS WIRE)–AmpliPhi Biosciences Corporation (NYSE American: APHB), a clinical-stage biotechnology company focused on the development of therapies for antibiotic-resistant infections using bacteriophage technology, today announced financial results for the third quarter ended September 30, 2017.   “I’m excited to report on the progress AmpliPhi made in the third quarter of 2017” Tweet this “I’m […]

Simulations Plus Reports FY2017 and Fourth Quarter FY2017 Financial Results

November 15, 2017

LANCASTER, Calif.–(BUSINESS WIRE)–Simulations Plus, Inc. (NASDAQ: SLP), a leading provider of software for pharmaceutical discovery and development, today reported its financial results for its 2017 fiscal year (FY17) and fourth quarter (4Q17) ended August 31, 2017.   Results for the 2017 fiscal year (FY17):   Revenues were $24.1 million, up 20.9% over $20.0 million in […]

NovaBay Pharmaceuticals Reports Third Quarter 2017 Financial Results

November 15, 2017

EMERYVILLE, Calif.–(BUSINESS WIRE)–NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a biopharmaceutical company focusing on commercializing prescription Avenova® for lid and lash hygiene in the domestic eye care market, reports financial results for the three and ninth months ended September 30, 2017 and provides a business update.   “This strategy is aimed at optimizing sales by effectively […]

GTx Provides Corporate Update and Reports Third Quarter 2017 Financial Results

November 15, 2017

MEMPHIS, Tenn.–(BUSINESS WIRE)–GTx, Inc. (Nasdaq:GTXI) today reported financial results for the third quarter of 2017 and highlighted recent accomplishments and upcoming milestones.   “Kegels in a Bottle: Preliminary Results of a Selective Androgen Receptor Modulator (GTx-024) for the Treatment of Stress Urinary Incontinence in Post-Menopausal Women” Tweet this “During the quarter, we achieved a key […]

Innovus Pharmaceuticals Reports Nine Month Net Revenue of $6.4 million and Net Loss Decrease of 51.6% Compared to the Same Period in 2016

November 15, 2017

SAN DIEGO–(BUSINESS WIRE)–Innovus Pharmaceuticals, Inc. (“Innovus Pharma” or the “Company”) (OTCQB: INNV) today announced third quarter 2017 net revenue of $2.2 million compared to $1.9 million in net revenue for the same period in 2016. Net revenue for the nine months ended September 30, 2017 was $6.4 million compared to $3.1 million for the same […]

Ligand Provides Highlights from Today’s Analyst Day Event

November 15, 2017

SAN DIEGO–(BUSINESS WIRE)–At an Analyst Day event held today in New York City, Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) reviewed the recent progress of its business, including its revenue growth opportunities, its portfolio of partnered assets and its OmniAb® and Captisol® technology platforms. Management also discussed its Glucagon Receptor Antagonist internal development program, provided 2017 financial […]

Sage Therapeutics Prices Public Offering of Common Stock

November 15, 2017

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Sage Therapeutics (Nasdaq: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced the pricing of an underwritten public offering of 3,529,411 shares of its common stock at a public offering price of $85.00 per share. The gross proceeds to Sage Therapeutics from the offering, […]

Inozyme Pharma Raises $49 Million in a Series A Financing to Develop Therapies for Rare Diseases Affecting Soft Tissues and Bone

November 15, 2017

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Inozyme Pharma, Inc., a biotechnology company developing novel medicines to treat rare diseases of calcification, affecting soft tissues and bone, today announced it has raised a $49 million Series A financing. The financing was led by Longitude Capital, and included participation from New Enterprise Associates (NEA), Novo Ventures and Sanofi Ventures.   “With […]

Xenetic Biosciences Reports 2017 Third Quarter Financial Results and Provides Corporate Update

November 15, 2017

LEXINGTON, Mass.–(BUSINESS WIRE)–Xenetic Biosciences, Inc. (NASDAQ: XBIO) (“Xenetic” or the “Company”), a clinical-stage biopharmaceutical company focused on the discovery, research and development of next-generation biologic drugs and novel orphan oncology therapeutics, announced today its unaudited financial results for the quarter ended September 30, 2017.   Xenetic also provided a corporate update and anticipated milestones for […]

Kalytera Announces Notice of Allowance of US Patent for Treatment of Graft Versus Host Disease

November 15, 2017

SAN FRANCISCO & TEL AVIV, Israel–(BUSINESS WIRE)–Kalytera Therapeutics, Inc. (TSX VENTURE: KALY and OTCQB: KALTF) (the “Company” or “Kalytera”) is pleased to announce that the United States Patent and Trademark Office has issued a Notice of Allowance for US Patent Application 15/143,694 covering the use of cannabidiol (“CBD”) in the treatment of graft versus host […]

Turnstone Biologics Appoints Dr. Mike Burgess as President of Research and Development

November 15, 2017

OTTAWA, Ontario & NEW YORK–(BUSINESS WIRE)–Turnstone Biologics, a clinical-stage immuno-oncology company, today announced the appointment of Mike Burgess, MBChB, Ph.D., as president of research and development. Dr. Burgess joins from Bristol-Myers Squibb, where he was senior vice president of development across multiple therapeutic areas. At Turnstone Biologics, he will lead all functions in the R&D […]

Immune Pharmaceuticals Announces Third Quarter 2017 Financial Results and Provides a Corporate Update

November 15, 2017

ENGLEWOOD CLIFFS, N.J.–(BUSINESS WIRE)–Immune Pharmaceuticals Inc. (NASDAQ:IMNP) (“Immune”) a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases, today announced financial results for the quarter ending September 30, 2017 and provided a corporate update.   “We believe this financing will enable us to achieve several important milestones” Tweet this Third […]

PAREXEL Expands Global Regulatory Services with Addition of Senior Executives from FDA and Oncology Industry

November 15, 2017

BOSTON–(BUSINESS WIRE)–PAREXEL, a leading global biopharmaceutical services provider, today announced the appointment of three former senior regulatory consulting executives from the U.S. Food and Drug Administration (FDA) and Oncology industry positions. The new hires are part of PAREXEL’s Global Integrated Product Development and Compliance team and will be focused on helping PAREXEL clients deliver commercially […]

FEEDBACK